Medicenna Therapeutics Corp. announced a subscription agreement of a non-brokered private placement of 5,141,388 common shares at a price of CAD1.95 per share for a gross proceeds CAD 10,025,706.6 and 5,141,388 pre-funded warrants to purchase 5,141,388 common shares at a price of CAD1.94 per share for a gross proceeds CAD 9,974,292.72, bringing total proceeds to CAD 19,999,999.32 on April 26, 2024. The transaction includes participation from RA Capital Healthcare Fund, L.P. The Offering is expected to close on or about April 30, 2024 and is subject to the approval of the TSX.